Arcutis Biotherapeutics, Inc.
ARQT
Rang in aandelen
#3998
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aandeelprijs
$32.53
Marktkapitalisatie
$4.09B
Verandering (1 dag)
1.99%
Verandering (1 jaar)
55.77%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Categorie
Healthcare
P/B-ratio voor Arcutis Biotherapeutics, Inc. (ARQT)
P/B-ratio op October 2026 TTM: 15.63
Volgens de meest recente financiële rapporten en aandelenkoers van Arcutis Biotherapeutics, Inc. is de huidige P/B-ratio (TTM) 15.63. Eind 2023 had het bedrijf een P/B-ratio van 2.52.
P/B-ratiohistoriek voor Arcutis Biotherapeutics, Inc. van 2017 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 15.63 | 46.05% |
| 2024 | 10.70 | 323.63% |
| 2023 | 2.52 | -35.03% |
| 2022 | 3.89 | 12.90% |
| 2021 | 3.44 | -7.15% |
| 2020 | 3.71 | -129.04% |
| 2019 | -12.77 | -61.23% |
| 2018 | -32.93 | 614.27% |
| 2017 | -4.61 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -60.00% |
US
|
|
| 13.2547 | -15.18% |
US
|
|
| 4.208 | -73.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.44% |
NL
|
